Cold, Cryoport isn’t even on the radar of the larger institutions, and likely won’t be for another year or two, so yeah you probably do know more about the company. You can hang your hat on that. If the smaller institutions don’t have the whole story, it’s because management isn’t sharing it, and that is the problem. Maybe the institutions you were talking to at that time were clueless, but they were performing the industry and company diligence that retail investors couldn’t possibly do, and that was my point. I did an internship at Prudential Securities in college and saw the caliber of people institutions hire, and the quality and quantity of research and analysis they perform, and was just passing that along.
I didn’t say that institutions are fairly valuing CYRX. Institutions have one motivation; and that is to make a profit. They will perform a valuation analysis, and if their analysis shows that it is fully valued, they won’t continue to buy it. I’m not going through the posts, but Robert said that their first price target was $9 and another one (when the price reached that) said that it wouldn’t get interesting again until new contracts were announced, or it sold off to around $6.
I think you may be reading too far into the McKesson partnership. The meeting on the Mesa was an industry conference with dozens of presentations, discussions and partnering opportunities. We know there is a lot going on behind the curtains at Cryoport and they are sitting on contracts that haven’t been announced. During the 2nd quarter conference call, they said they weren’t ready to announce the Kite contract . . YET. Then about a week after Novartis received approval for Kymriah, they announced the contract with Kite, apparently to keep the momentum going.
